Combination therapy does not meet primary endpoints in first-line PD-L1-high metastatic non-small cell lung cancer
Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients ...
13 Sep 01:50 · Medical Xpress